Product
Risperidone
Aliases
Oral Risperidone, Placebo to risperidone, Risperdal, Risperidone 3 mg
Name
Risperidone
INN Name
Risperidone
FDA Approved
Yes
24 clinical trials
1 organization
15 indications
1 document
Indication
SchizophreniaIndication
Schizoaffective DisorderIndication
ChoreaIndication
Antipsychotics and Neuroleptics ToxicityIndication
DepressionIndication
PsychosisIndication
Food-drug InteractionIndication
Drug Administration ScheduleIndication
Drug TherapyIndication
Antipsychotic AgentsIndication
Serum Glutathione LevelIndication
Bipolar DisorderIndication
Huntington's diseaseIndication
ApathyClinical trial
A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in RwandaStatus: Completed, Estimated PCD: 2019-12-02
Clinical trial
A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of SchizophreniaStatus: Active (not recruiting), Estimated PCD: 2024-07-15
Clinical trial
A Multi Dose, Open-Label, Parallel-Group Study to Evaluate the PK and Safety/Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2023-11-03
Clinical trial
A Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Injection of Quarterly Risperidone (QUAR) for Different Formulations and Dose Strengths in Participants With Schizophrenia (QUARTZ Study)Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant (DLP-114)Status: Completed, Estimated PCD: 2023-02-10
Clinical trial
A Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2022-06-21
Clinical trial
An Open-Label, Multiple Dose, Safety and Pharmacokinetic Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Patients With Chronic, Stable Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2015-09-01
Clinical trial
A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With SchizophreniaStatus: Completed
Clinical trial
Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM® at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2014-02-01
Clinical trial
Risperidone ISM® Effectiveness in Schizophrenia Patients Hospitalised Due to A Relapse: a Prospective Non-interventional Evaluation (RESHAPE Study)Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Risperidone for the Treatment of Huntington's Disease ChoreaStatus: Completed, Estimated PCD: 2023-12-30
Clinical trial
The Characteristics of Treatment Resistant Schizophrenia From the Illness OnsetStatus: Not yet recruiting, Estimated PCD: 2024-10-12
Clinical trial
Synergistic Effect of Vitamin E & D in Reducing the Risk of Effects Associated With Atypical AntipsychoticsStatus: Completed, Estimated PCD: 2021-06-01
Clinical trial
Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
KF2022#3-tutkimus: Teen ja Kolajuoman Vaikutus Risperidoni-oraaliliuoksen ImeytymiseenStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
"Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing"Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
The Relationship Between the Efficacy of Lumateperone and Central Glutamate and Dopaminergic Metabolism: A Comparison With Risperidone in First Episode PsychosisStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIALStatus: Not yet recruiting, Estimated PCD: 2024-05-02
Clinical trial
A Randomized Controlled Trial to Evaluate Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With SchizophreniaStatus: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode SchizophreniaStatus: Completed, Estimated PCD: 2012-11-01
Clinical trial
Biomarkers of Conversion Risk and Treatment Response in Early-Stage SchizophreniaStatus: Completed, Estimated PCD: 2023-05-31
Clinical trial
Longitudinal Comparative Effectiveness of Bipolar Disorder TherapiesStatus: Terminated, Estimated PCD: 2019-06-30
Clinical trial
Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare SettingsStatus: Completed, Estimated PCD: 2024-04-16
Clinical trial
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.Status: Recruiting, Estimated PCD: 2026-12-01
Document
DailyMed Label: Risperidone Organization
Ratiopharm Inc